Onkologie - Prognosemarker uPA/PAI-1 als Hilfe zur individuellen Therapieentscheidung beim nodalnegativen Mammakarzinom

Literatur

• 01 Harbeck N , Schmitt M , Meisner C , Friedel C , Untch M , Schmidt M , Lisboa B , Sweep  , Jänicke F , Thomssen C . Chemo NO Study Group .ASCO 2009, Abstract #511. 
• 02 Harris L , Fritsche H , Mennel R , Norton L , Ravdin P , Taube S , Somerfield M R, Hayes D F, Bast Jr R C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.  J Clin Oncol. 2007;  25 5287-5312
• 03 Jänicke F , Prechtl A , Thomssen C , Harbeck N , Meisner C , Untch M , Sweep C G, Selbmann H K, Graeff H , Schmitt M . for the German "Chemo-N0" Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.  J Natl Cancer Inst.. 2001;  93 (12) 913-20
• 04 Thomssen C , Harbeck N , Dittmer J , Abraha-Späth S R, Papendick N , Paradiso A , Lisboa B , Jänicke F , Schmitt M , Vetter M . Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.  J Natl Cancer Inst.. 2009;  101 (14) 1028-9